ADAPTIMMUNE THERAPEUTICS PLC
Income Statement
| Line Item | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $178.0M | $60.3M | $27.1M | $6.1M | $4.0M | $1.1M | $59.5M | $37.8M |
| Cost of Revenue | $70.0K | — | — | — | — | — | — | — |
| Gross Profit | $178.0M | — | — | — | — | — | — | — |
| Gross Margin | 100.0% | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $149.1M | $126.5M | $127.7M | $111.1M | $91.6M | $97.5M | $98.3M | $87.4M |
| SG&A Expense | $87.3M | $73.5M | $63.4M | $57.3M | $45.8M | $43.4M | $43.6M | $31.1M |
| Operating Income | $-68.8M | $-139.7M | $-164.0M | $-162.2M | $-133.4M | $-139.8M | $-82.4M | $-80.7M |
| Operating Margin | -38.6% | -231.8% | -604.0% | -2,638.6% | -3,370.5% | -12,457.2% | -138.4% | -213.2% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-67.2M | $-112.5M | $-163.0M | $-157.3M | $-129.9M | $-136.9M | $-95.0M | $-69.7M |
| Income Tax Expense | $3.6M | $1.3M | $2.5M | $791.0K | $162.0K | $242.0K | $497.0K | $451.0K |
| Net Income | $-70.8M | $-113.9M | $-165.5M | $-158.1M | $-130.1M | $-137.2M | $-95.5M | $-70.1M |
| Net Margin | -39.8% | -188.9% | -609.5% | -2,571.0% | -3,286.8% | -12,225.0% | -160.5% | -185.4% |
| EPS (Basic) | $-0.05 | $-0.09 | $-0.17 | $-0.17 | $-0.15 | $-0.22 | $-0.16 | $-0.13 |
| EPS (Diluted) | $-0.05 | $-0.09 | $-0.17 | $-0.17 | $-0.15 | $-0.22 | $-0.16 | $-0.13 |
| Shares Outstanding (Basic) | 1.51B | 1.21B | 967.2M | 934.8M | 854.8M | 629.8M | 627.5M | 562.1M |
| Shares Outstanding (Diluted) | 1.51B | 1.21B | 967.2M | 934.8M | 854.8M | 629.8M | 627.5M | 562.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |